MULTIZ321
TUG Member
- Joined
- Jun 6, 2005
- Messages
- 31,350
- Reaction score
- 9,013
- Points
- 1,048
- Location
- FT. LAUDERDALE, FL
- Resorts Owned
-
BLUEWATER BY SPINNAKER HHI
ROYAL HOLIDAY CLUB RHC (POINTS)
AstraZaeneca's Lynparza Shown to Put Brakes on Ovarian Cancer
By Ludwig Burger/ Science News/ Reuters/ reuters.com
"MUNICH (Reuters) - An AstraZeneca drug that blocks a cancer cell’s ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class.
Given as a maintenance therapy to reinforce initial chemotherapy, Lynparza halted or reversed tumor growth in 60 percent of patients three years into the trial. Only 28 percent of those in a chemotherapy-only control group were spared tumor progression at that stage.
At year four, the progression-free survival (PFS) rate in the Lynparza group was still above 50 percent, against 11 percent for chemotherapy alone.
“The results ... herald a new era in treatment for women diagnosed with advanced ovarian cancer who carry a BRCA mutation,” said Kathleen Moore, associate professor at the University of Oklahoma’s Stephenson Cancer Center, who presented the results at the European Society for Medical Oncology in Munich on Sunday....."
Richard
By Ludwig Burger/ Science News/ Reuters/ reuters.com
"MUNICH (Reuters) - An AstraZeneca drug that blocks a cancer cell’s ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class.
Given as a maintenance therapy to reinforce initial chemotherapy, Lynparza halted or reversed tumor growth in 60 percent of patients three years into the trial. Only 28 percent of those in a chemotherapy-only control group were spared tumor progression at that stage.
At year four, the progression-free survival (PFS) rate in the Lynparza group was still above 50 percent, against 11 percent for chemotherapy alone.
“The results ... herald a new era in treatment for women diagnosed with advanced ovarian cancer who carry a BRCA mutation,” said Kathleen Moore, associate professor at the University of Oklahoma’s Stephenson Cancer Center, who presented the results at the European Society for Medical Oncology in Munich on Sunday....."
Richard